What if veterinarians could give families more quality time with a pet they love?
Cancer is a devastating disease not only for humans, but for pets as well. Research shows approximately 25 percent of all dogs will die as a result of cancer and veterinarians agree better therapies are needed to help manage cancer in dogs.1
Lymphoma is one of the most common cancers in dogs and often progresses rapidly. B-Cell lymphoma is the most common type of lymphoma and one that’s most responsive to treatment. T-Cell lymphoma is less common and can be fatal within weeks if left untreated. Sadly, some of the most popular breeds of dogs are at the highest risk of lymphoma and the incidence increases as they age.2
Inspired by advances in human cancer treatment, Aratana has two canine-specific monoclonal antibody (MAb) therapies to aid in the treatment of lymphoma. Our MAb for B-Cell lymphoma, BLONTRESS®, is fully licensed by the U.S. Department of Agriculture (USDA) as an aid in the treatment of dogs with B-cell lymphoma. TACTRESS® is indicated as an aid in the treatment of dogs with T-cell lymphoma and has been fully licensed by the USDA.
Osteosarcoma is the most common bone tumor found in dogs. Bone cancer can affect any breed of dog, but it is more commonly found in the larger breeds. The disease is extremely aggressive and has a tendency to spread rapidly into other parts of the dog’s body. Without effective treatment, the prognosis for the dog tends to be poor.3
We continue to research new options for lymphoma and osteosarcoma in dogs. Explore our research and information on cancer in dogs in the Aratana Library.
1. “Learning From Dogs with Cancer.” New York Times. http://well.blogs.nytimes.com/2015/10/21/learning-from-dogs-with-cancer/?_r=0
2. “Lymphoma in Dogs.” PetMD.com. http://www.petmd.com/dog/conditions/cancer/c_dg_lymphoma
3. “Bone Cancer in Dogs.” American Kennel Club Canine Health Foundation. http://www.akcchf.org/canine-health/your-dogs-health/bone-cancer-in-dogs.html?referrer=https://www.google.com/